Durable medical equipment

Lifeward CEO Issues Open Letter to Shareholders on Progress to Finalize Exoskeleton Medicare Payment Rate

Retrieved on: 
Monday, April 1, 2024
HCPCS, Durable medical equipment, Disability, Freedom, Face, Robotics, DBA, Macs, Medicare, CMS, SCI, Rehabilitation

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, today issued an open letter from Larry Jasinski, Chief Executive Officer, to shareholders discussing the Company’s progress with the Centers for Medicare & Medicaid Services (“CMS”) to establish a payment rate for ReWalk Personal Exoskeletons. The full letter is published below:

Key Points: 
  • As a result of the deferral, the payment rate is not included in CMS’ April 2024 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (“DMEPOS”) fee schedule of Medicare payment rates that are effective April 1.
  • Our active engagement with CMS is ongoing and we work to establish the payment rate as soon as possible.
  • Until a payment rate for exoskeletons is added to the DMEPOS schedule, the Medicare Administrative Contractors (“MACs”) still have authority to approve and pay claims on a case-by-case basis with discretion to set the payment rate.
  • Lifeward intends to submit an additional 60-75 additional Medicare claims by the end of 2024 to accelerate its momentum in expanding access for qualified Medicare beneficiaries.

Neurolutions, Inc. Announces Groundbreaking CMS Decision for IpsiHand™: A Leap Forward in Stroke Rehabilitation

Retrieved on: 
Tuesday, March 12, 2024
Health, Hospitals, Neurology, Health Technology, Practice Management, Physical Therapy, HCPCS, Durable medical equipment, Brain, BCI, Patient, DME, Stroke, Classification, Survivor, Medicare, FDA, CMS, Movement, Rehabilitation, Medical device

E0738 will be used to describe “Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education, including microprocessor, all components and accessories” to describe the IpsiHand Upper Extremity Rehabilitation System.

Key Points: 
  • E0738 will be used to describe “Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education, including microprocessor, all components and accessories” to describe the IpsiHand Upper Extremity Rehabilitation System.
  • The IpsiHand System is a breakthrough therapeutic device and the only FDA-cleared, commercially available solution that enables non-invasive, at-home rehabilitation for stroke survivors affected by chronic motor deficits.
  • CMS’ decision also includes a final Medicare benefit category determination, classifying the IpsiHand as Durable Medical Equipment (DME).
  • Neurolutions is proud to partner with CMS to advance the forefront of the rapidly-growing frontier of BCI enabled post-stroke neurorehabilitation.

Bonafide and Synthpop announce partnership at MedTrade 2024

Retrieved on: 
Tuesday, March 26, 2024
AI, Partnership, Durable medical equipment, Patient, DME, Software, Health, HME, Medical device

DALLAS, March 26, 2024 /PRNewswire/ -- In a groundbreaking move poised to revolutionize the patient intake and resupply processes, Bonafide and Synthpop have announced a strategic partnership.

Key Points: 
  • DALLAS, March 26, 2024 /PRNewswire/ -- In a groundbreaking move poised to revolutionize the patient intake and resupply processes, Bonafide and Synthpop have announced a strategic partnership.
  • The announcement comes during MedTrade 2024, the year's most anticipated Durable Medical Equipment (DME) conference.
  • Synthpop uses advanced AI solutions to streamline workflows, making it a perfect match to enhance and scale the Bonafide product offering.
  • The announcement of this partnership at MedTrade 2024 underscores both companies' commitment to advancing healthcare technology and improving patient outcomes.

CMS awards Noridian Medicare DME contract for third time

Retrieved on: 
Tuesday, March 5, 2024
Durable medical equipment, CMS, FFS, Medicare, JD, DME, Pharmaceutical industry

FARGO, N.D., March 05, 2024 (GLOBE NEWSWIRE) -- Noridian Healthcare Solutions, LLC (Noridian) , a leader in developing solutions for federal, state and commercial health care programs, proudly announces the re-award of the Durable Medical Equipment (DME) Medicare Jurisdiction D (JD) contract.

Key Points: 
  • FARGO, N.D., March 05, 2024 (GLOBE NEWSWIRE) -- Noridian Healthcare Solutions, LLC (Noridian) , a leader in developing solutions for federal, state and commercial health care programs, proudly announces the re-award of the Durable Medical Equipment (DME) Medicare Jurisdiction D (JD) contract.
  • The Centers for Medicare & Medicaid Services (CMS) recently re-awarded Noridian the $152.8 million contract, concluding a full-and-open competitive procurement.
  • Territories, Noridian processes more than 13 million fee-for-service (FFS) claims for nearly 25,000 DME suppliers, resulting in $2.6 billion in payments for the JD contract.
  • For nearly two decades, Noridian has diligently served the suppliers and beneficiaries of JD,” said Noridian president and CEO Jon Bogenreif.

UnitedHealth Group Update on Change Healthcare Cyberattack

Retrieved on: 
Friday, March 8, 2024
Security, Health, Technology, Practice Management, Health Insurance, Managed Care, Pharmacy, Medicine, Optum, Durable medical equipment, Electronic prescribing, Part, Change Healthcare, Manager, Medicare, Patient, Medicare Part D, UnitedHealth Group, Medicaid, Environment, Software, Health insurance

UnitedHealth Group continues to make substantial progress in mitigating the impact to consumers and care providers of the unprecedented cyberattack on the U.S. health system and the Change Healthcare claims and payment infrastructure.

Key Points: 
  • UnitedHealth Group continues to make substantial progress in mitigating the impact to consumers and care providers of the unprecedented cyberattack on the U.S. health system and the Change Healthcare claims and payment infrastructure.
  • “We are committed to providing relief for people affected by this malicious attack on the U.S. health system,” said Andrew Witty, CEO of UnitedHealth Group.
  • We’re determined to make this right as fast as possible.”
    Based on our ongoing investigation, there is no indication that any other UnitedHealth Group systems have been affected by this attack.
  • For more information and access to all solutions provided by UnitedHealth Group, visit http://www.uhg.com/changehealthcarecyberresponse .

Dexcom G7, the Smallest, Most Accurate, Easy-to-Use CGM Now Connects to the Tandem t:slim X2 Insulin Pump

Retrieved on: 
Wednesday, December 6, 2023
Health, Medical Devices, Diabetes, Technology, Health Technology, Software, Biotechnology, Durable medical equipment, Insulin, Garmin, AID, Automated insulin delivery system, Risk, DXCM, CGM, Tandem Diabetes Care, Tandem, Multimedia, Pharmacy, DME, MD, Dexcom, Diabetic retinopathy, Hypoglycemia, G6, Medical device, Pharmaceutical industry, Video game, Apple, Glycated hemoglobin

View the full release here: https://www.businesswire.com/news/home/20231206143334/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231206143334/en/
    Dexcom G7 CGM now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in the U.S. (Photo: Business Wire)
    “There’s a reason Dexcom is the undisputed leader in CGM connectivity and the clear choice for AID systems,” said Jake Leach, executive vice president and chief operating officer at Dexcom.
  • Tandem t:slim X2 pumps pre-loaded with Dexcom G7 integration are now shipping to new customers.
  • To learn more and to get started with Dexcom G7 and the Tandem t:slim X2 insulin pump today, visit Dexcom.com/tandem .
  • Dexcom G7 and t:slim X2 insulin pump connectivity is expected to launch in additional countries outside the U.S. in early 2024.

NanoVibronix Issues Letter to Shareholders

Retrieved on: 
Tuesday, November 14, 2023
Biotechnology, General Health, Medical Devices, Other Health, Health, University of Southampton, National Health Service, Durable medical equipment, Third-party administrator, Organization, Patient satisfaction, Gold, Insurance, Patient, Compensated emancipation, NHS, COVID-19, CMS, University, SAW, Partnership, Growth, Medicare, Veterans Health Administration, Pharmaceutical industry, Health insurance, Marketing

NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to shareholders from its Chief Executive Officer, Brian Murphy, providing a review of the third quarter 2023 and recent business developments.

Key Points: 
  • NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to shareholders from its Chief Executive Officer, Brian Murphy, providing a review of the third quarter 2023 and recent business developments.
  • We recorded revenues of $458,000 for the quarter ended September 30, 2023 with a loss from operations of $670,000.
  • In the relative year-to-date period, revenues increased 22% and the loss from operations was reduced by approximately 20%.
  • CMS invited NanoVibronix to a public meeting to present our findings and to answer CMS’s questions, which was held June 1, 2023.

Thermedical Awarded $3 Million NIH Grant to Study Promising Treatment for Ventricular Tachycardia, a Leading Cause of Sudden Cardiac Death

Retrieved on: 
Tuesday, October 10, 2023
Medical Devices, Health, Hospitals, Surgery, Clinical Trials, Cardiology, Arrhythmia, National Heart, Lung, and Blood Institute, FHRS, Vanderbilt University Medical Center, Safety, Lung, Facial muscles, FDA, SERF, Clinical trial, Durable medical equipment, Bangladesh Technical Education Board, Shock, Ventricular tachycardia, Patient, Quality of life, NIH, ICD, Pharmaceutical industry, Medical device

VT is an abnormally rapid heart rhythm that is a leading cause of sudden cardiac death worldwide.

Key Points: 
  • VT is an abnormally rapid heart rhythm that is a leading cause of sudden cardiac death worldwide.
  • Sudden cardiac death kills 325,000 adults in the U.S. every year1.
  • "SERF ablation is a new approach that has the potential to improve treatment of this arrhythmia.
  • Today, VT patients with ICDs who experience VT episodes may be treated with conventional RF ablation, a lengthy procedure with a moderate success rate of approximately 50%.

Helius Medical Technologies, Inc. Receives UPC Numbers for its PoNS® System and Mouthpiece

Retrieved on: 
Thursday, September 28, 2023
Management of multiple sclerosis, Helios, CMS, GTIN, Pons, HSDT, UPC, Prescription, Pharmacy, Medicare, PBM, Durable medical equipment, Global Trade Item Number, HCPCS, Wolters Kluwer, GameChanger, Health care

NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that its Portable Neuromodulation Stimulator (“PoNS®”) system and mouthpiece have been assigned universal product code (“UPC”) numbers by Wolters Kluwer Health – Medi-Span® (“Medi-Span”). Medi-Span is the leading automated clinical screening solution– providing a data backbone and vital support to payers, pharmacy benefit managers (“PBMs”), wholesalers, and manufacturers.

Key Points: 
  • The PoNS system has been assigned the Global Trade Item Number (“GTIN”) of 00864288000462, with a direct price of $25,700.
  • Consequently, this will allow Helius to pursue reimbursement through both the pharmacy and the Durable Medical Equipment (“DME”)/HCPCS pathways.
  • “Receiving UPC numbers for the PoNS system and mouthpiece is a gamechanger for Helius,” said Dane Andreeff, Helius’ President and Chief Executive Officer.
  • "We will now be able to reference these UPC numbers as we negotiate reimbursement with third party payers, and prescriptions can be written with these UPC numbers.

Great Elm Group Reports Fiscal 2023 Fourth Quarter and Full Year Financial Results

Retrieved on: 
Wednesday, September 20, 2023
Executive, REIT, Financial result, Sale, Durable medical equipment, AUM, EBITDA, Acquisition, Investment, Monomoy, Greenbriar Capital Corp, Conference, GEG, Real estate, Cryptocurrency, Video game, Management, Tobacco, Recycling, Bookkeeping, Great Elm

WALTHAM, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Great Elm Group, Inc. (“we,” “our,” “GEG,” “Great Elm,” or “the Company”), (NASDAQ: GEG), an alternative asset manager, today announced financial results for its fiscal fourth quarter and year ended June 30, 2023.

Key Points: 
  • WALTHAM, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Great Elm Group, Inc. (“we,” “our,” “GEG,” “Great Elm,” or “the Company”), (NASDAQ: GEG), an alternative asset manager, today announced financial results for its fiscal fourth quarter and year ended June 30, 2023.
  • GEG collected incentive fees from Great Elm Capital Corp. (“GECC") for the first time in the Company’s history, totaling $1.0 million for the fourth quarter.
  • On May 15, 2023, GEG’s Board of Directors appointed Keri Davis as Chief Financial Officer of Great Elm, expanding upon her role as Chief Financial Officer of GECC.
  • Discussion of Financial Results for the Fiscal Year Ended June 30, 2023
    Total revenue for the fiscal year ended June 30, 2023 increased 92% to $8.7 million from $4.5 million in the prior fiscal year.